Cargando…

ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer

Immunogenic cell death (ICD) is a novel cell death mechanism that activates and regulates the immune system against cancer. However, its prognostic value in liver cancer remains unclear. Here, several algorithms such as correlation analysis, Cox regression analysis, and Lasso regression analysis wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Duntao, Zhang, Zeyu, Xia, Fada, Liang, Qiuju, Liu, Yuanhong, Liu, Wei, Xu, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285067/
https://www.ncbi.nlm.nih.gov/pubmed/37361216
http://dx.doi.org/10.3389/fphar.2023.1202823
_version_ 1785061530054688768
author Su, Duntao
Zhang, Zeyu
Xia, Fada
Liang, Qiuju
Liu, Yuanhong
Liu, Wei
Xu, Zhijie
author_facet Su, Duntao
Zhang, Zeyu
Xia, Fada
Liang, Qiuju
Liu, Yuanhong
Liu, Wei
Xu, Zhijie
author_sort Su, Duntao
collection PubMed
description Immunogenic cell death (ICD) is a novel cell death mechanism that activates and regulates the immune system against cancer. However, its prognostic value in liver cancer remains unclear. Here, several algorithms such as correlation analysis, Cox regression analysis, and Lasso regression analysis were carried out to evaluate the prognostic value of ICD-related genes in patients with liver cancer. Three ICD-related prognostic genes, the prion protein gene (PRNP), dynamin 1-like gene (DNM1L), and caspase-8 (CASP8), were identified and used to construct a risk signature. Patients with liver cancer were categorized into high- and low-risk groups using the ICD-related signature. Subsequently, a multivariate regression analysis revealed that the signature was an independent risk factor in liver cancer [hazard ratio (HR) = 6.839; 95% confidence interval (CI) = 1.625–78.785]. Patient survival was also predicted using the risk model, with area under the curve values of 0.75, 0.70, and 0.69 for 1-, 3-, and 5-year survival, respectively. Finally, a prognostic nomogram containing the clinical characteristics and risk scores of patients was constructed. The constructed ICD-related signature could serve as a prognostic and immunotherapeutic biomarker in liver cancer.
format Online
Article
Text
id pubmed-10285067
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102850672023-06-23 ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer Su, Duntao Zhang, Zeyu Xia, Fada Liang, Qiuju Liu, Yuanhong Liu, Wei Xu, Zhijie Front Pharmacol Pharmacology Immunogenic cell death (ICD) is a novel cell death mechanism that activates and regulates the immune system against cancer. However, its prognostic value in liver cancer remains unclear. Here, several algorithms such as correlation analysis, Cox regression analysis, and Lasso regression analysis were carried out to evaluate the prognostic value of ICD-related genes in patients with liver cancer. Three ICD-related prognostic genes, the prion protein gene (PRNP), dynamin 1-like gene (DNM1L), and caspase-8 (CASP8), were identified and used to construct a risk signature. Patients with liver cancer were categorized into high- and low-risk groups using the ICD-related signature. Subsequently, a multivariate regression analysis revealed that the signature was an independent risk factor in liver cancer [hazard ratio (HR) = 6.839; 95% confidence interval (CI) = 1.625–78.785]. Patient survival was also predicted using the risk model, with area under the curve values of 0.75, 0.70, and 0.69 for 1-, 3-, and 5-year survival, respectively. Finally, a prognostic nomogram containing the clinical characteristics and risk scores of patients was constructed. The constructed ICD-related signature could serve as a prognostic and immunotherapeutic biomarker in liver cancer. Frontiers Media S.A. 2023-06-08 /pmc/articles/PMC10285067/ /pubmed/37361216 http://dx.doi.org/10.3389/fphar.2023.1202823 Text en Copyright © 2023 Su, Zhang, Xia, Liang, Liu, Liu and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Su, Duntao
Zhang, Zeyu
Xia, Fada
Liang, Qiuju
Liu, Yuanhong
Liu, Wei
Xu, Zhijie
ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer
title ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer
title_full ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer
title_fullStr ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer
title_full_unstemmed ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer
title_short ICD-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer
title_sort icd-related risk model predicts the prognosis and immunotherapy response of patients with liver cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285067/
https://www.ncbi.nlm.nih.gov/pubmed/37361216
http://dx.doi.org/10.3389/fphar.2023.1202823
work_keys_str_mv AT suduntao icdrelatedriskmodelpredictstheprognosisandimmunotherapyresponseofpatientswithlivercancer
AT zhangzeyu icdrelatedriskmodelpredictstheprognosisandimmunotherapyresponseofpatientswithlivercancer
AT xiafada icdrelatedriskmodelpredictstheprognosisandimmunotherapyresponseofpatientswithlivercancer
AT liangqiuju icdrelatedriskmodelpredictstheprognosisandimmunotherapyresponseofpatientswithlivercancer
AT liuyuanhong icdrelatedriskmodelpredictstheprognosisandimmunotherapyresponseofpatientswithlivercancer
AT liuwei icdrelatedriskmodelpredictstheprognosisandimmunotherapyresponseofpatientswithlivercancer
AT xuzhijie icdrelatedriskmodelpredictstheprognosisandimmunotherapyresponseofpatientswithlivercancer